Ibio Inc (IBIO)

$0.85 +0.02 (2.37%)
Market Cap 16.41M
Revenue (ttm) 230,000.00
Net Income (ttm) -24.91M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -10,830.43%
Debt to Equity Ratio 0.07
Volume 394,245
Avg Vol 1,281,012
Day's Range N/A - N/A
Shares Out 19.66M
Stochastic %K 40%
Beta 0.86
Analysts Strong Sell
Price Target $3.30

Company Profile

iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the...

Industry: Biotechnology
Sector: Healthcare
Phone: 979 446 0027
Website: ibioinc.com
Address:
11750 Sorrento Valley Road, Suite 200, San Diego, United States
flawlesssqueeze
flawlesssqueeze Sep. 8 at 6:51 PM
$IBIO all aboard the IBIO train!
0 · Reply
2pumps1dump
2pumps1dump Sep. 8 at 6:23 PM
$IBIO
0 · Reply
TortillaDePatata
TortillaDePatata Sep. 8 at 3:04 PM
$IBIO Can you smell it?
1 · Reply
FullThrottle1
FullThrottle1 Sep. 8 at 11:11 AM
$IBIO Nobody believes in this 💩.
1 · Reply
sixmilliondollarman
sixmilliondollarman Sep. 7 at 9:17 PM
$IBIO 👀 NHP data on deck! Last Q (IBIO fiscal Q3) update was also released on a Friday and followed by release of rodent data Monday. Typical playbook. Quiet period from Q end to PR. (Zero conferences, analysts etc). Biz update usually comes first so it’s not overshadowed, in this case by data. NHP data for IBIO-610 is material at this stage of development. Could come tomorrow. If not 🔜
0 · Reply
Joelew22
Joelew22 Sep. 5 at 6:17 PM
$IBIO interesting timing for report I wasn't anticipating it until late September. Have a great weekend!
1 · Reply
TreeShade
TreeShade Sep. 5 at 5:34 PM
$IBIO Excellent article! Big updates imminent! 🤑 🤑 https://www.sdbj.com/life-sciences/biotech-life-sciences/ibio-sets-sights-on-clinic-for-treatments-of-obesity-heart-disease/
1 · Reply
RDMoneylover
RDMoneylover Sep. 5 at 4:09 PM
$LIXT Lets take this to $10.00 and $SNDL and $SKYE and $IBIO
2 · Reply
RDMoneylover
RDMoneylover Sep. 5 at 4:05 PM
$LIXT let get it to $10.00 $SNDL $IBIO and $SKYE
0 · Reply
d_risk
d_risk Sep. 5 at 3:18 PM
$IBIO - iBio, Inc. - 10K - Updated Risk Factors IBIO’s risk factors now highlight sharply rising R&D and commercialization costs, urgent funding needs despite recent capital raises, new limits on capital access due to low public float, expanded clinical and regulatory hurdles, heavy reliance on third parties and collaborators, major IP and cybersecurity vulnerabilities, and new risks from climate change and acquisitions. #Biotechnology #IPVulnerabilities #RegulatoryHurdles #FundingRisk #R&DCosts 🟢 Added 🟠 Removed https://d-risk.ai/IBIO/10-K/2025-09-05
1 · Reply
Latest News on IBIO
iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

Sep 5, 2025, 7:30 AM EDT - 3 days ago

iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

iBio Announces Closing of $50 Million Public Offering

Aug 25, 2025, 7:00 AM EDT - 14 days ago

iBio Announces Closing of $50 Million Public Offering

iBio Announces Pricing of $50 Million Public Offering

Aug 19, 2025, 8:01 AM EDT - 20 days ago

iBio Announces Pricing of $50 Million Public Offering

iBio Announces Proposed Public Offering

Aug 18, 2025, 4:01 PM EDT - 21 days ago

iBio Announces Proposed Public Offering

iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

Jun 24, 2025, 7:00 AM EDT - 2 months ago

iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call

Jun 23, 2025, 4:15 PM EDT - 2 months ago

iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call

iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment

Jun 16, 2025, 7:00 AM EDT - 3 months ago

iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment

iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model

May 5, 2025, 8:00 AM EDT - 4 months ago

iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model

iBio Reports Fiscal Third Quarter 2025 Financial Results

May 2, 2025, 8:00 AM EDT - 4 months ago

iBio Reports Fiscal Third Quarter 2025 Financial Results

iBio Raises $6.2 Million Through Warrant Inducement Transaction

Apr 29, 2025, 1:43 PM EDT - 4 months ago

iBio Raises $6.2 Million Through Warrant Inducement Transaction

iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio

Apr 22, 2025, 8:00 AM EDT - 4 months ago

iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio

iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline

Apr 7, 2025, 7:00 AM EDT - 5 months ago

iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline

iBio to Begin Trading on the Nasdaq Stock Exchange

Feb 19, 2025, 4:05 PM EST - 7 months ago

iBio to Begin Trading on the Nasdaq Stock Exchange

iBio Reports Fiscal Second Quarter 2025 Financial Results

Feb 10, 2025, 4:05 PM EST - 7 months ago

iBio Reports Fiscal Second Quarter 2025 Financial Results

iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio

Jan 2, 2025, 7:00 AM EST - 8 months ago

iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio

iBio Reports Fiscal First Quarter 2025 Financial Results

Nov 12, 2024, 4:05 PM EST - 10 months ago

iBio Reports Fiscal First Quarter 2025 Financial Results

iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Sep 20, 2024, 4:05 PM EDT - 1 year ago

iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

iBio to Participate in Upcoming Investor Conferences

Sep 3, 2024, 7:00 AM EDT - 1 year ago

iBio to Participate in Upcoming Investor Conferences

iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development

Aug 12, 2024, 4:30 PM EDT - 1 year ago

iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development

iBio Closes Sale of Manufacturing Facility in Texas

Jun 3, 2024, 7:00 AM EDT - 1 year ago

iBio Closes Sale of Manufacturing Facility in Texas

iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

May 13, 2024, 4:05 PM EDT - 1 year ago

iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

iBio stock nearly tripled on Wednesday: here's why

Mar 27, 2024, 2:43 PM EDT - 1 year ago

iBio stock nearly tripled on Wednesday: here's why

iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases

Mar 27, 2024, 7:00 AM EDT - 1 year ago

iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases

iBio Announces $15.0 Million Private Placement

Mar 26, 2024, 7:35 PM EDT - 1 year ago

iBio Announces $15.0 Million Private Placement

iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka

Feb 26, 2024, 7:45 AM EST - 1 year ago

iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka

iBio Announces Participation in 23rd Annual PepTalk Conference

Jan 16, 2024, 8:15 AM EST - 1 year ago

iBio Announces Participation in 23rd Annual PepTalk Conference

Top 4 Health Care Stocks That May Rocket Higher In Q1 - AlloVir (NASDAQ:ALVR), GRI Bio (NASDAQ:GRI)

Jan 16, 2024, 6:50 AM EST - 1 year ago

Top 4 Health Care Stocks That May Rocket Higher In Q1 - AlloVir (NASDAQ:ALVR), GRI Bio (NASDAQ:GRI)

ALVR GRI VYNE

iBio Amends and Extends Maturity of Credit Agreement

Dec 26, 2023, 7:15 AM EST - 1 year ago

iBio Amends and Extends Maturity of Credit Agreement

iBio, Inc. Announces Pricing of $4.5 Million Public Offering

Dec 5, 2023, 8:00 AM EST - 1 year ago

iBio, Inc. Announces Pricing of $4.5 Million Public Offering

iBio Announces Reverse Stock Split

Nov 27, 2023, 5:20 PM EST - 1 year ago

iBio Announces Reverse Stock Split

iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific

Nov 1, 2023, 8:24 AM EDT - 2 years ago

iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific

iBio Explains Recent Filing of Registration Statement

Oct 2, 2023, 6:45 AM EDT - 2 years ago

iBio Explains Recent Filing of Registration Statement

iBio Announces Filing of 2023 Annual Report on SEC Form 10-K

Sep 27, 2023, 4:19 PM EDT - 2 years ago

iBio Announces Filing of 2023 Annual Report on SEC Form 10-K

iBio Announces Amendment to Credit Agreement with Woodforest

Sep 21, 2023, 4:05 PM EDT - 2 years ago

iBio Announces Amendment to Credit Agreement with Woodforest

iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development

Aug 14, 2023, 4:15 PM EDT - 2 years ago

iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development

iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company's Next Stage of Growth

Jun 27, 2023, 8:00 AM EDT - 2 years ago

iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company's Next Stage of Growth

iBio Forges Research Collaboration with the National Institutes of Health

Jun 12, 2023, 4:15 PM EDT - 2 years ago

iBio Forges Research Collaboration with the National Institutes of Health

iBio to Participate in the JMP Securities Life Sciences Conference

May 9, 2023, 4:30 PM EDT - 2 years ago

iBio to Participate in the JMP Securities Life Sciences Conference

iBio Discovers New Panel of CD3 T-Cell Binding Antibodies Using its Patented AI Epitope Steering Platform

Apr 4, 2023, 4:05 PM EDT - 2 years ago

iBio Discovers New Panel of CD3 T-Cell Binding Antibodies Using its Patented AI Epitope Steering Platform

iBio Advances Anti-CCR8 Antibody Program to Preclinical In Vivo Testing

Mar 31, 2023, 8:10 AM EDT - 2 years ago

iBio Advances Anti-CCR8 Antibody Program to Preclinical In Vivo Testing

iBio Announces MUC16 as its Latest Immune-Oncology Target Program

Feb 16, 2023, 4:48 PM EST - 2 years ago

iBio Announces MUC16 as its Latest Immune-Oncology Target Program

iBio Announces Closing of $3.5 Million Underwritten Public Offering

Dec 9, 2022, 4:05 PM EST - 2 years ago

iBio Announces Closing of $3.5 Million Underwritten Public Offering

iBio Announces Pricing of $3.5 Million Underwritten Public Offering

Dec 6, 2022, 11:27 PM EST - 2 years ago

iBio Announces Pricing of $3.5 Million Underwritten Public Offering

iBio Announces Proposed Underwritten Public Offering

Dec 6, 2022, 4:01 PM EST - 2 years ago

iBio Announces Proposed Underwritten Public Offering

iBio® to Showcase the RubrYc® Discovery Engine During Poster Presentations at Antibody Engineering & Therapeutics Conference 2022

Dec 5, 2022, 8:00 AM EST - 3 years ago

iBio® to Showcase the RubrYc® Discovery Engine During Poster Presentations at Antibody Engineering & Therapeutics Conference 2022

iBio Announces CEO Departure

Dec 2, 2022, 4:30 PM EST - 3 years ago

iBio Announces CEO Departure

iBio, Inc. (IBIO) Q4 2022 Results - Earnings Call Transcript

Sep 27, 2022, 10:33 PM EDT - 3 years ago

iBio, Inc. (IBIO) Q4 2022 Results - Earnings Call Transcript

iBio Reports Preliminary Unaudited Fiscal Year 2022 Financial Results and Provides Corporate Update

Sep 27, 2022, 4:10 PM EDT - 3 years ago

iBio Reports Preliminary Unaudited Fiscal Year 2022 Financial Results and Provides Corporate Update

iBio Acquires RubrYc Therapeutics' AI Drug Discovery Platform and Pipeline

Sep 21, 2022, 8:30 AM EDT - 3 years ago

iBio Acquires RubrYc Therapeutics' AI Drug Discovery Platform and Pipeline

iBio, Inc. (IBIO) CEO Tom Isett on Q3 2022 Results - Earnings Call Transcript

May 12, 2022, 9:19 PM EDT - 3 years ago

iBio, Inc. (IBIO) CEO Tom Isett on Q3 2022 Results - Earnings Call Transcript

flawlesssqueeze
flawlesssqueeze Sep. 8 at 6:51 PM
$IBIO all aboard the IBIO train!
0 · Reply
2pumps1dump
2pumps1dump Sep. 8 at 6:23 PM
$IBIO
0 · Reply
TortillaDePatata
TortillaDePatata Sep. 8 at 3:04 PM
$IBIO Can you smell it?
1 · Reply
FullThrottle1
FullThrottle1 Sep. 8 at 11:11 AM
$IBIO Nobody believes in this 💩.
1 · Reply
sixmilliondollarman
sixmilliondollarman Sep. 7 at 9:17 PM
$IBIO 👀 NHP data on deck! Last Q (IBIO fiscal Q3) update was also released on a Friday and followed by release of rodent data Monday. Typical playbook. Quiet period from Q end to PR. (Zero conferences, analysts etc). Biz update usually comes first so it’s not overshadowed, in this case by data. NHP data for IBIO-610 is material at this stage of development. Could come tomorrow. If not 🔜
0 · Reply
Joelew22
Joelew22 Sep. 5 at 6:17 PM
$IBIO interesting timing for report I wasn't anticipating it until late September. Have a great weekend!
1 · Reply
TreeShade
TreeShade Sep. 5 at 5:34 PM
$IBIO Excellent article! Big updates imminent! 🤑 🤑 https://www.sdbj.com/life-sciences/biotech-life-sciences/ibio-sets-sights-on-clinic-for-treatments-of-obesity-heart-disease/
1 · Reply
RDMoneylover
RDMoneylover Sep. 5 at 4:09 PM
$LIXT Lets take this to $10.00 and $SNDL and $SKYE and $IBIO
2 · Reply
RDMoneylover
RDMoneylover Sep. 5 at 4:05 PM
$LIXT let get it to $10.00 $SNDL $IBIO and $SKYE
0 · Reply
d_risk
d_risk Sep. 5 at 3:18 PM
$IBIO - iBio, Inc. - 10K - Updated Risk Factors IBIO’s risk factors now highlight sharply rising R&D and commercialization costs, urgent funding needs despite recent capital raises, new limits on capital access due to low public float, expanded clinical and regulatory hurdles, heavy reliance on third parties and collaborators, major IP and cybersecurity vulnerabilities, and new risks from climate change and acquisitions. #Biotechnology #IPVulnerabilities #RegulatoryHurdles #FundingRisk #R&DCosts 🟢 Added 🟠 Removed https://d-risk.ai/IBIO/10-K/2025-09-05
1 · Reply
TrustedInvestor77
TrustedInvestor77 Sep. 5 at 2:36 PM
$IBIO I thought this BS company was already gone..🤣🤣🤣
0 · Reply
DARKP00L
DARKP00L Sep. 5 at 12:42 PM
$IBIO 07:34 on Sep. 05 2025 iBio Says Revenues For The Fiscal Year Ended June 30, 2025, Were Approximately $0.4M, An Increase Of $0.2M Over Fiscal Year 2024. #tradeideas
0 · Reply
2pumps1dump
2pumps1dump Sep. 5 at 11:35 AM
$IBIO https://www.globenewswire.com/news-release/2025/09/05/3145217/0/en/iBio-Reports-Fiscal-Year-2025-Financial-Results-and-Provides-Corporate-Update.html
1 · Reply
suredubb
suredubb Sep. 4 at 7:12 PM
$IBIO insiders buying at $2.77 a share for $500,000… nobody selling.. good things take time
0 · Reply
skitime
skitime Sep. 4 at 4:33 PM
$IBIO Darn, hope you folks took your profit$ on Monday AH pump!
1 · Reply
Fishnet88
Fishnet88 Sep. 4 at 1:28 PM
$IBIO It’s time to sold over 1,3 $ again. 👌
0 · Reply
2pumps1dump
2pumps1dump Sep. 3 at 7:39 PM
$IBIO news on the way?
0 · Reply
suredubb
suredubb Sep. 3 at 6:29 PM
$IBIO steadily climbing is beautiful…. accumulation
0 · Reply
PenguSummer6000
PenguSummer6000 Sep. 3 at 5:41 PM
$IBIO
0 · Reply
TreeShade
TreeShade Sep. 3 at 4:51 PM
$IBIO A slow, upward coil 🐍 is always a turn on! 🤑 ... especially with data results on the horizon.
1 · Reply
sixmilliondollarman
sixmilliondollarman Sep. 3 at 4:10 PM
$IBIO 👀 June PR said NHP data for 610 early Q4 and June call said end of Q3. Data any time! IBIO fiscal year end was June. Year end update within 2 1/2 weeks.
0 · Reply
flawlesssqueeze
flawlesssqueeze Sep. 3 at 2:53 PM
$IBIO
1 · Reply